Novo Nordisk is planning to expand its manufacturing operations with US$65 million at its 264-acre campus in Clayton, North Carolina.
The company will initiate the expansion by the end of 2018 and the expansion will add more than two dozen new positions including operational side.
The 18-job expansion project is for Novo Nordisk’s growing Diabetes Finished Products (DFP) facility, responsible for the formulation, filling, inspection, assembly and packaging of diabetes and obesity medicines.
The construction is expected to be completed by the fourth quarter of 2019, with full operations starting in 2020.
Clayton facility will add 300 employees in 2018, mostly, manufacturing associates and technicians for the API expansion, as well as positions in IT, automation, metrology and others.
On the other hand, the company’s API operations will formulate ingredients for Novo Nordisk’s portfolio of diabetes medicines, including insulin’s and liraglutide.
Formulation of semaglutide may be a consideration for this site in the future.